Adaptimmune, GlaxoSmithKline deal
Adaptimmune and GlaxoSmithKline expanded a 2014 deal to co-develop autologous T cell receptor (TCR) therapies. Under the expanded deal, Adaptimmune will start by year end a pivotal trial of GSK3377794 to treat synovial sarcoma and will explore starting pivotal trials in myxoid round cell liposarcoma. Additionally, the companies now may start up to eight proof-of-principle studies of the TCR therapy targeting cancer/testis antigen 1B (NY-ESO-1; CTAG1B) in combination with other therapies, including checkpoint inhibitors. Adaptimmune will conduct the studies and will be responsible for identifying potential combinations. GSK has the right to nominate up to four additional targets for co-development. GSK will fund the pivotal studies, and the companies will share the costs of the combination trials. ...